Next-generation medicine: Combining BCR-ABL and hedgehog-targeted therapies

Kim Hien T. Dao; Jeffrey W. Tyner

doi:10.1158/1078-0432.CCR-12-3934

Next-generation medicine: Combining BCR-ABL and hedgehog-targeted therapies

Kim Hien T. Dao, Jeffrey W. Tyner

Knight Cancer Institute

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Disease relapse remains a major cause of death in patients with BCR-ABL-positive leukemia despite advances in treatment with kinase inhibitors. Significant efforts are underway to target pathways that maintain leukemia stem cells. Targeting these pathways holds promise for definitive leukemia eradication or improvement of the effectiveness of currently available therapies.

Original language	English (US)
Pages (from-to)	1309-1311
Number of pages	3
Journal	Clinical Cancer Research
Volume	19
Issue number	6
DOIs	https://doi.org/10.1158/1078-0432.CCR-12-3934
State	Published - Mar 15 2013

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-12-3934

Cite this

@article{0b8b87bfe7084ee98e3ee287565b1cb3,

title = "Next-generation medicine: Combining BCR-ABL and hedgehog-targeted therapies",

abstract = "Disease relapse remains a major cause of death in patients with BCR-ABL-positive leukemia despite advances in treatment with kinase inhibitors. Significant efforts are underway to target pathways that maintain leukemia stem cells. Targeting these pathways holds promise for definitive leukemia eradication or improvement of the effectiveness of currently available therapies.",

author = "Dao, {Kim Hien T.} and Tyner, {Jeffrey W.}",

year = "2013",

month = mar,

day = "15",

doi = "10.1158/1078-0432.CCR-12-3934",

language = "English (US)",

volume = "19",

pages = "1309--1311",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "6",

}

TY - JOUR

T1 - Next-generation medicine

T2 - Combining BCR-ABL and hedgehog-targeted therapies

AU - Dao, Kim Hien T.

AU - Tyner, Jeffrey W.

PY - 2013/3/15

Y1 - 2013/3/15

N2 - Disease relapse remains a major cause of death in patients with BCR-ABL-positive leukemia despite advances in treatment with kinase inhibitors. Significant efforts are underway to target pathways that maintain leukemia stem cells. Targeting these pathways holds promise for definitive leukemia eradication or improvement of the effectiveness of currently available therapies.

AB - Disease relapse remains a major cause of death in patients with BCR-ABL-positive leukemia despite advances in treatment with kinase inhibitors. Significant efforts are underway to target pathways that maintain leukemia stem cells. Targeting these pathways holds promise for definitive leukemia eradication or improvement of the effectiveness of currently available therapies.

UR - http://www.scopus.com/inward/record.url?scp=84875208239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875208239&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-3934

DO - 10.1158/1078-0432.CCR-12-3934

M3 - Article

C2 - 23382113

AN - SCOPUS:84875208239

SN - 1078-0432

VL - 19

SP - 1309

EP - 1311

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 6

ER -

Next-generation medicine: Combining BCR-ABL and hedgehog-targeted therapies

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this